Gene expression profile of murine cutaneous melanoma after systemic treatment with tumor necrosis factor (TNF) associated or not with melphalan (MEL).

ABSTRACT: Cutaneous melanomas are malignant radio and chemoresistant neoplasias presenting high morbidity and elevated mortality rates. Isolated Limb Perfusion (ILP) with Melphalan (Mel) is used in the treatment of non-resectable locally advanced melanomas of extremity sparing the limb from amputation in 40-50% of the cases. Adding the Tumor Necrosis Factor alpha (Tnfa) improves total complete response to 70-90%. The cellular and molecular mechanisms underlying the changes promoted by Mel and Tnfa are not completely understood. In this study we evaluated the impact of systemic Mel and Tnfa administration on tumor growth, analyzed the morphological changes promoted by each treatment, and searched for early molecular targets of Mel and Tnfa, alone or in combination, in a murine melanoma model. Morphol

ORGANISM(S): Mus musculus

SUBMITTER: Renato Puga 

PROVIDER: E-GEOD-21559 | biostudies-arrayexpress |

REPOSITORIES: biostudies-arrayexpress